Toxic Exposures Translational Research Award
ID: 355158Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Toxic Exposures Translational Research Award (TERP TRA) to support impactful translational research focused on military-related toxic exposures. This grant aims to accelerate the movement of promising ideas into clinical applications, including health care products and interventions, while addressing the health outcomes and mitigation strategies associated with toxic exposures faced by Service Members, Veterans, and their families. With an estimated total program funding of $12.8 million and an expected six awards, the application process includes a pre-application deadline of August 13, 2024, and a full application deadline of November 7, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Defense (DOD) has announced the FY24 Toxic Exposures Translational Research Award aimed at advancing research related to military-related toxic exposures. This funding opportunity, part of the Defense Health Program, is seeking impactful translational research that identifies causes, health outcomes, and mitigation strategies associated with toxic exposures faced by Service Members, Veterans, and their families. The program has specific submission deadlines, including a pre-application by August 13, 2024, and a full application by November 7, 2024, with a total funding of $30 million available. Key research goals include elucidating mechanisms of adverse health effects, developing diagnostics and therapies, and enhancing prevention strategies. Eligible applicants encompass a range of organizations, including academic institutions and non-profits, with emphasis on collaboration with DOD and VA researchers. Applications should demonstrate an understanding of how proposed research will translate into clinical applications, benefiting both military and civilian populations while adhering to the defined exclusionary criteria regarding classified research and clinical trials. The review process highlights rigorous criteria for assessing proposals to ensure the advancement of relevant medical research initiatives.
    Similar Opportunities
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    DOD Glioblastoma, Transformative Consortium Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Glioblastoma Transformative Consortium Award, aimed at advancing research to improve outcomes for glioblastoma patients. This grant seeks proposals for innovative, multidisciplinary projects that collectively address a central hypothesis, requiring collaboration among at least four distinct projects and the inclusion of a consumer advocate. With an estimated total program funding of $9 million, the application process includes a pre-application deadline of December 23, 2024, and a full application deadline of January 13, 2025. Interested applicants can reach the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507 for further assistance.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Active
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Tactical Behaviors for Autonomous Maneuver
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Funding Opportunity Title:Deployed Warfighter Protection (DWFP) Program for the Protection of Deployed Military Personnel from Threats Posed by Arthropod Disease Vectors
    Active
    Department of Defense
    The Department of Defense is offering a funding opportunity through the Fiscal Year 2025 Deployed Warfighter Protection (DWFP) Program, aimed at safeguarding military personnel from threats posed by arthropod disease vectors. The program seeks innovative research proposals focused on developing new insecticides, personal protection technologies, and improved vector control strategies, with applications required to address specific research areas such as bite prevention, vector control, and diagnostics. This initiative is crucial for enhancing health protection in military operations and has a total estimated funding of $5 million, with individual awards capped at $975,000 over three years. Interested applicants must submit a pre-application by October 4, 2024, and a full application by January 28, 2025; for further inquiries, contact Scott I. Hoffman at scott.i.hoffman2.civ@army.mil or call 1-520-671-1470.
    Department of Army Energetics Basic Research Center (EBRC) Fiscal Year 2025
    Active
    Dept of the Army -- Materiel Command
    The Department of the Army, through the Materiel Command, is offering a funding opportunity for the Energetics Basic Research Center (EBRC) for Fiscal Year 2025, aimed at advancing research in energetic materials (EM) critical to U.S. national security. This initiative invites eligible applicants, including universities, nonprofit organizations, state and local governments, and for-profit entities, to submit white papers and proposals that focus on innovative research in EMs, particularly in areas such as novel materials, microstructure influence, and advanced diagnostics. The program is designed to enhance the Army's capabilities in developing new materials and technologies that improve weapon systems' performance and effectiveness, with a total funding ceiling of $1 million anticipated for up to six awards ranging from $60,000 to $250,000 per year. Interested parties should submit white papers by January 6, 2025, and proposals by invitation by April 7, 2025; for further inquiries, contact Schon Zwakman at schon.m.zwakman.civ@army.mil or by phone at 919-541-4722.
    Fundamental Research to Counter Weapons of Mass Destruction
    Active
    Defense Threat Reduction Agency
    The Defense Threat Reduction Agency (DTRA) has announced a Broad Agency Announcement (BAA) for fundamental research aimed at countering Weapons of Mass Destruction (WMD), with funding available from October 1, 2024, to September 30, 2034. This opportunity invites proposals from accredited colleges, universities, and research entities to contribute to DTRA's mission of reducing WMD threats, emphasizing collaboration in areas such as chemical and biological defense. The funding will primarily be awarded as grants, with amounts ranging from $25,000 to $1 million annually, and proposals will undergo a two-phase evaluation process assessing scientific merit and mission relevance. Interested applicants should submit pre-application white papers and can direct inquiries to the BAA Administrative Mailbox at dtra.belvoir.rd.mbx.rd-cb-frbaa25-34-a@mail.mil before the closing date of September 30, 2034.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.